Prothrombin
Star0
Identification
- Summary
Prothrombin is a coagulation factor used for emergency reversal of vitamin K antagonist therapy.
- Brand Names
- Balfaxar, Beriplex, Kcentra, Octaplex
- Generic Name
- Prothrombin
- DrugBank Accession Number
- DB11311
- Background
Prothrombin Complex Concentrate (Human), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Blood factors - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
>sp|P00734|THRB_HUMAN Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY GFYTHVFRLKKWIQKVIDQFGE
Download FASTA Format- Synonyms
- Coagulation factor II (human)
- Coagulation factor II human
- Factor II
- Factor II (prothrombin)
- Human coagulation factor II
Pharmacology
- Indication
For use in the emergency reversal of coagulation factor deficiency in patients receiving vitamin K antagonist therapy. Prothrombin is administered as part of a cocktail containing several coagulation factors.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AFibrinogen alpha chain cleavageHumans AFibrinogen beta chain cleavageHumans ACoagulation factor XIII A chain agonistHumans ACarboxypeptidase B2 agonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Approximately 60h 1.
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The therapeutic efficacy of Prothrombin can be decreased when used in combination with Abciximab. Acenocoumarol The therapeutic efficacy of Prothrombin can be decreased when used in combination with Acenocoumarol. Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Prothrombin. Alteplase The therapeutic efficacy of Prothrombin can be decreased when used in combination with Alteplase. Aminocaproic acid The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Prothrombin. Ancrod The therapeutic efficacy of Prothrombin can be decreased when used in combination with Ancrod. Anistreplase The therapeutic efficacy of Prothrombin can be decreased when used in combination with Anistreplase. Antithrombin Alfa The therapeutic efficacy of Prothrombin can be decreased when used in combination with Antithrombin Alfa. Antithrombin III human The therapeutic efficacy of Prothrombin can be decreased when used in combination with Antithrombin III human. Apixaban The therapeutic efficacy of Prothrombin can be decreased when used in combination with Apixaban. Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Balfaxar Prothrombin (26 [iU]/1mL) + Coagulation Factor IX Human (25.5 [iU]/1mL) + Coagulation factor VII human (16.5 [iU]/1mL) + Coagulation factor X human (24 [iU]/1mL) + Protein C (22 [iU]/1mL) + Protein S human (22 [iU]/1mL) Powder, for solution Intravenous Octapharma USA Inc 2023-07-21 Not applicable US Beriplex P/n 1000 Prothrombin (1600 unit) + Coagulation Factor IX Human (1240 unit) + Coagulation factor VII human (1000 unit) + Coagulation factor X human (2040 unit) + Protein C (1640 unit) + Protein S human (1360 unit) Powder, for solution Intravenous Csl Behring 2013-11-21 Not applicable Canada Beriplex P/N 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung Prothrombin (1360 IE) + Coagulation Factor IX Human (1020 IE) + Coagulation factor VII human (700 IE) + Coagulation factor X human (1640 IE) + Protein C (1200 I.E.) + Protein S human (1000 IE) Injection, powder, for solution Parenteral Csl Behring 2013-04-16 Not applicable Austria Beriplex P/N 250 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung Prothrombin (340 I.E.) + Coagulation Factor IX Human (255 IE) + Coagulation factor VII human (175 IE) + Coagulation factor X human (410 IE) + Protein C (300 IE) + Protein S human (250 IE) Injection, powder, for solution Parenteral Csl Behring 2008-02-27 Not applicable Austria Beriplex P/n 500 Prothrombin (800 unit) + Coagulation Factor IX Human (620 unit) + Coagulation factor VII human (500 unit) + Coagulation factor X human (1020 unit) + Protein C (820 unit) + Protein S human (680 unit) Powder, for solution Intravenous Csl Behring 2011-07-28 Not applicable Canada Beriplex P/N 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung Prothrombin (680 IE) + Coagulation Factor IX Human (510 IE) + Coagulation factor VII human (350 IE) + Coagulation factor X human (820 IE) + Protein C (600 I.E.) + Protein S human (500 IE) Injection, powder, for solution Parenteral Csl Behring 2008-02-27 Not applicable Austria Cofact 250 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung Prothrombin (245 IE) + Coagulation Factor IX Human (250 IE) + Coagulation factor VII human (135 IE) + Coagulation factor X human (245 IE) Injection, powder, for solution Parenteral Prothya Biosolutions Netherlands b.v. 2007-05-18 Not applicable Austria COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET Prothrombin (245 IU) + Coagulation Factor IX Human (250 IU) + Coagulation factor VII human (135 IU) + Coagulation factor X human (245 IU) + Protein C (250 IU) + Protein S human (45 IU) Injection Intravenous CENTURION İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey Cofact 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung Prothrombin (490 IE) + Coagulation Factor IX Human (500 IE) + Coagulation factor VII human (270 IE) + Coagulation factor X human (490 IE) Injection, powder, for solution Parenteral Prothya Biosolutions Netherlands b.v. 2007-05-18 Not applicable Austria COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET Prothrombin (490 IU) + Coagulation Factor IX Human (500 IU) + Coagulation factor VII human (270 IU) + Coagulation factor X human (490 IU) + Protein C (500 IU) + Protein S human (90 IU) Injection Intravenous CENTURION İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 8FB1K07F16
- CAS number
- 9001-26-7
References
- General References
- Palta S, Saroa R, Palta A: Overview of the coagulation system. Indian J Anaesth. 2014 Sep;58(5):515-23. doi: 10.4103/0019-5049.144643. [Article]
- External Links
- FDA label
- Download (638 KB)
- MSDS
- Download (77.5 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Bleeding / Blood Loss During Surgery / Cardiovascular Surgical Procedures / Fresh Frozen Plasma / Prothrombin Complex Concentrates 1 4 Completed Treatment Hemophilia A 1 4 Recruiting Treatment Coagulation Disorder / Massive Hemorrhage / Traumatic haemorrhage 1 4 Withdrawn Treatment Postpartum Haemorrhage (PPH) 1 3 Completed Treatment Acute Major Bleeding / Coagulation Disorder 1 3 Completed Treatment Cardiovascular Disease (CVD) 1 3 Completed Treatment High Bleeding Risk 1 3 Completed Treatment Reversal of Anticoagulant Treatment 1 3 Completed Treatment Reversal of Coagulopathy 1 3 Recruiting Treatment Acute Major Bleeding 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Intravenous Injection Intravenous Powder, for solution Intravenous Injection, powder, lyophilized, for solution; kit Intravenous Powder, for solution Parenteral Kit; powder, for solution Intravenous Injection, powder, for solution Intravenous drip 520 IU/vial Injection, powder, for solution Parenteral Solution Intravenous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
- Not Available
Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsFibrinogen alpha chain
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Cleavage
- General Function
- Structural molecule activity
- Specific Function
- Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function ...
- Gene Name
- FGA
- Uniprot ID
- P02671
- Uniprot Name
- Fibrinogen alpha chain
- Molecular Weight
- 94972.455 Da
References
2. DetailsFibrinogen beta chain
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Cleavage
- General Function
- Structural molecule activity
- Specific Function
- Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function...
- Gene Name
- FGB
- Uniprot ID
- P02675
- Uniprot Name
- Fibrinogen beta chain
- Molecular Weight
- 55927.9 Da
References
3. DetailsCoagulation factor XIII A chain
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Protein-glutamine gamma-glutamyltransferase activity
- Specific Function
- Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl-epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibr...
- Gene Name
- F13A1
- Uniprot ID
- P00488
- Uniprot Name
- Coagulation factor XIII A chain
- Molecular Weight
- 83266.805 Da
References
- Palta S, Saroa R, Palta A: Overview of the coagulation system. Indian J Anaesth. 2014 Sep;58(5):515-23. doi: 10.4103/0019-5049.144643. [Article]
4. DetailsCarboxypeptidase B2
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Cleaves C-terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins in the circulation thereby regulating their activities. Down-regulates fibrinolysis...
- Gene Name
- CPB2
- Uniprot ID
- Q96IY4
- Uniprot Name
- Carboxypeptidase B2
- Molecular Weight
- 48423.85 Da
References
- Palta S, Saroa R, Palta A: Overview of the coagulation system. Indian J Anaesth. 2014 Sep;58(5):515-23. doi: 10.4103/0019-5049.144643. [Article]
Enzymes
1. DetailsCoagulation factor X
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Serine-type endopeptidase activity
- Specific Function
- Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
- Gene Name
- F10
- Uniprot ID
- P00742
- Uniprot Name
- Coagulation factor X
- Molecular Weight
- 54731.255 Da
References
- Palta S, Saroa R, Palta A: Overview of the coagulation system. Indian J Anaesth. 2014 Sep;58(5):515-23. doi: 10.4103/0019-5049.144643. [Article]
Drug created at December 03, 2015 16:52 / Updated at May 21, 2021 10:21